- Home
- GERN vs DBD Comparison
GERN vs DBD Comparison
Compare GERN & DBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- DBD
- Stock Information
- Founded
- GERN 1990
- DBD 1859
- Country
- GERN United States
- DBD United States
- Employees
- GERN N/A
- DBD N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- DBD EDP Services
- Sector
- GERN Health Care
- DBD Technology
- Exchange
- GERN Nasdaq
- DBD Nasdaq
- Market Cap
- GERN 1.5B
- DBD N/A
- IPO Year
- GERN 1996
- DBD N/A
- Fundamental
- Price
- GERN $1.55
- DBD $43.57
- Analyst Decision
- GERN Buy
- DBD Strong Buy
- Analyst Count
- GERN 11
- DBD 2
- Target Price
- GERN $5.80
- DBD $65.00
- AVG Volume (30 Days)
- GERN 14.9M
- DBD 137.6K
- Earning Date
- GERN 05-01-2025
- DBD 05-01-2025
- Dividend Yield
- GERN N/A
- DBD N/A
- EPS Growth
- GERN N/A
- DBD N/A
- EPS
- GERN N/A
- DBD N/A
- Revenue
- GERN $76,994,000.00
- DBD $3,751,100,000.00
- Revenue This Year
- GERN $208.83
- DBD $1.73
- Revenue Next Year
- GERN $57.49
- DBD $1.60
- P/E Ratio
- GERN N/A
- DBD N/A
- Revenue Growth
- GERN 32386.92
- DBD N/A
- 52 Week Low
- GERN $1.46
- DBD $30.37
- 52 Week High
- GERN $5.34
- DBD $51.81
- Technical
- Relative Strength Index (RSI)
- GERN 31.37
- DBD 45.49
- Support Level
- GERN $1.63
- DBD $42.56
- Resistance Level
- GERN $1.89
- DBD $45.31
- Average True Range (ATR)
- GERN 0.11
- DBD 1.32
- MACD
- GERN 0.03
- DBD 0.04
- Stochastic Oscillator
- GERN 0.37
- DBD 28.12
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.